Mainz Biomed has initiated the ColoFuture clinical study to assess the integration of a new mRNA biomarkers portfolio into its ColoAlert test for colorectal cancer (CRC).
ColoAlert is an easy-to-use, non-invasive test designed to detect tumour DNA and CRC cases in the earliest stages from stool samples.
Last month, the company acquired an exclusive option to in-license the new gene expression (mRNA) biomarkers from the Universite de Sherbrooke in Canada.
These biomarkers have been shown to have the ability to detect curable precancerous colonic polyps and treatable early-stage CRC.
